DiaMedica Pharma - DMAC Earnings per share for the last 12 months

Official company branding of DiaMedica Therapeutics Inc (DMAC)

The current status of DiaMedica Therapeutics (DMAC) is based on the patents for the drug DM199, the success of which is determined by the results of medical trials. The EPS value trend on GURU.Markets, reaching -4.60, complements data on strategic alliances with hospitals to attract capital. Meanwhile, DiaMedica Therapeutics delegates protein production and testing to external contractors, maintaining a significant dependence on third-party capacities.

DMAC: DiaMedica Pharma Net earnings per share (EPS TTM) 02/11/2024 - 11/18/2026

DiaMedica Therapeutics Inc. - analytical breakdowns and key metrics (DMAC)

Fundamental company valuation:DMAC (DiaMedica Therapeutics Inc.)
Core merchandise of diamedica.com

For DiaMedica Therapeutics (DMAC), the year-over-year (TTM) EPS comparison serves as an indicator of the efficiency of development capitalization. This metric measures the percentage change in net income per share over a year, reflecting profitability dynamics. The calculation is based on the difference between the current and previous twelve-month periods. Amid geopolitical barriers and clinical trial disruptions, sharp peaks on the chart signal a risk of future margin compression.